ELAN vs COR vs PAHC Stock Comparison

Elanco Animal Health, Cencora and Phibro Animal Health Prices as of Nov 13, 2026 Peers: Industry group
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
3 wins

Head to Head

11 decided of 12

Phibro Animal Health leads on 6 of the 12 questions below (Phibro Animal Health 6, Cencora 3, Elanco Animal Health 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANCORPAHCLeader
Larger companyMarket capitalisation $13.25B $69.10B $1.42B COR
Cheaper on earningsLower P/E, profitable companies only -90.2x 22.6x 13.9x PAHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 18.8x 10.6x PAHC
Faster revenue growthRevenue growth, trailing twelve months +12.1% +5.0% +10.1% ELAN
More profitableNet margin, trailing twelve months -2.9% — 6.7% PAHC
Better return on capitalReturn on invested capital 6.9% — 13.9% PAHC
Less leveragedLower net debt / EBITDA 2.3x — 2.1x PAHC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +21.8% -1.8% -19.5% ELAN
Better 5-year returnAnnualised price return, 5 years -4.1%/yr +23.4%/yr +9.6%/yr COR
Less volatileAnnualised volatility, 1 year 43.4% 33.4% 56.9% COR
Higher overall scoreMean of the five percentile scores vs peers 69/100 56/100 72/100 PAHC

Percentile Scorecard

ELANCORPAHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANCORPAHC
Valuation 92 #52 of 660 54 #13 of 27 95 #34 of 660
Growth 67 #208 of 619 64 #10 of 26 93 #46 of 619
Profitability 85 #90 of 595 64 #10 of 26 86 #86 of 595
Financial Health 31 #473 of 683 – 27 #496 of 683
Shareholder Returns 73 #126 of 459 41 #11 of 18 57 #196 of 459
Overall 69 56 72
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • PAHC ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANCORPAHCSPY
1 month +18.8%+6.8%-5.2% -2.0%
3 months +13.2%+14.4%+4.7% -2.8%
6 months +34.9%+39.3%+4.7% +2.0%
Year to date +18.4%+6.3%-3.7% +10.6%
1 year +21.8%-1.8%-19.5% +12.2%
3 years +136.2%+84.7%+253.7% +68.1%
3 years, per year +33.2%+22.7%+52.4% +18.9%
5 years -18.9%+186.4%+58.0% +61.4%
5 years, per year -4.1%+23.4%+9.6% +10.1%
10 years —+354.9%+25.3% +248.5%
10 years, per year —+16.4%+2.3% +13.3%

Risk

MeasureELANCORPAHCSPY
Volatility, 1Y 43.4%33.4%56.9% 13.6%
Downside volatility, 1Y 43.7%40.0%62.8% 13.9%
Beta vs S&P 500, 1Y 1.320.050.97 1.00
Return / volatility, 1Y 0.50-0.05-0.34 0.90
Max drawdown, 5Y -75.0%-32.6%-56.8% -25.4%
From 52-week high -0.2%-4.2%-39.6% -3.2%
52-week high $26.84$374.75$59.58 $779.14
52-week low $19.80$252.74$28.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANCORPAHC
P/E now vs peer median -91.1xmedian 17.0x 22.6xmedian 25.2x 14.2xmedian 17.0x
P/S now vs peer median 2.6xmedian 8.4x 0.2xmedian 0.4x 0.9xmedian 8.4x
EV/EBITDA now vs peer median 11.8xmedian 14.6x —median 14.5x 7.8xmedian 14.6x
P/FCF now vs peer median 32.8xmedian 19.0x 14.5xmedian 16.5x 22.2xmedian 19.0x
P/B now vs peer median 2.0xmedian 2.0x 18.6xmedian 2.7x 3.5xmedian 2.0x
PEG now vs peer median -1.82median 0.43 —median 1.72 0.14median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANCORPAHC
Revenue $5.15B $337.40B $1.54B
Gross profit $2.89B $13.87B $521.27M
Operating income $720.00M $3.93B $192.78M
Net income -$147.00M $3.51B $108.21M
Free cash flow $408.00M – $65.64M
R&D $381.00M – –
EPS (diluted) $-0.29 – $2.51
Cash & equivalents $465.00M $4.88B $75.55M
Total debt $3.71B – $610.88M
Shares (diluted) 506.50M 193.94M 40.96M
Enterprise value $11.29B $69.10B $1.11B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANCORPAHC
P/E -91.1x 22.6x 14.2x
P/FCF 32.8x 14.5x 22.2x
P/Operating cash flow 21.8x 14.3x 15.3x
P/S 2.6x 0.2x 0.9x
P/B 2.0x 18.6x 3.5x
P/Tangible book 3.7x 18.6x 3.7x
EV/EBITDA 11.8x – 7.8x
EV/EBIT 23.1x – 10.3x
EV/Revenue 3.2x 0.2x 1.3x
EV/FCF 40.8x – 30.3x
EV/Operating cash flow 27.1x 14.3x 20.8x
PEG (3Y EPS CAGR) -1.82 – 0.14

Growth

14 metrics
MetricELANCORPAHC
Revenue growth (1Y) 12.1% 5.0% 10.1%
Revenue CAGR (3Y) 5.6% 8.8% 16.4%
Gross profit growth (1Y) 14.6% 20.8% 19.5%
Gross profit CAGR (3Y) 4.9% 15.7% 20.6%
Operating income growth (1Y) 20.6% 49.5% 33.8%
Operating income CAGR (3Y) 41.2% 18.9% 49.7%
Net income growth (1Y) -508.3% 124.0% 47.3%
Net income CAGR (3Y) 49.5% 26.3% 243.2%
EPS growth (1Y) -500.5% – 51.2%
EPS CAGR (3Y) 50.0% – 104.0%
Operating cash flow growth (1Y) -2.4% 23.6% 122.6%
Operating cash flow CAGR (3Y) 69.1% 7.0% 24.0%
Free cash flow growth (1Y) 10.9% – 198.5%
Free cash flow CAGR (3Y) 117.8% – 30.6%

Profitability

14 metrics
MetricELANCORPAHC
Gross margin 56.2% – 33.8%
EBITDA margin 27.5% – 16.5%
Operating margin 14.0% – 12.5%
Pretax margin -1.8% – 9.1%
Net margin -2.9% – 6.7%
FCF margin 7.9% – 4.3%
Operating cash flow margin 11.9% 1.4% 6.2%
Return on equity -2.2% 101.2% 25.6%
Return on assets -1.1% 4.1% 6.8%
Return on invested capital 6.9% – 13.9%
Return on capital employed 6.2% – 15.9%
Asset turnover 0.4x 3.9x 1.0x
Cash conversion (OCF / net income) -4.2x 1.4x 0.9x
Stock comp / revenue 1.5% – 0.1%

Financial Health

11 metrics
MetricELANCORPAHC
Debt / assets 27.8% – 40.3%
Debt / equity 0.6x – 1.5x
Net debt / EBITDA 2.3x – 2.1x
Debt / FCF 9.1x – 9.3x
Liabilities / assets 50.3% – 72.4%
Equity / assets 49.7% 4.2% 27.6%
Interest coverage 2.8x – 4.2x
Current ratio 2.1x 0.9x 3.2x
Quick ratio 0.9x – 1.0x
Cash ratio 0.3x – 0.3x
Altman Z-score 1.72 – 3.10

Shareholder Returns

7 metrics
MetricELANCORPAHC
Dividend yield – 0.9% 1.3%
Net buyback yield -0.3% – –
Shareholder yield -0.3% 0.9% 1.3%
Payout ratio (earnings) – – 18.0%
Payout ratio (FCF) – – 29.7%
Dividend growth (1Y) – – 0.1%
Dividend CAGR (3Y) – – 0.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANCORPAHC
Forward P/E 23.7xFY2026 18.8xFY2027 10.6xFY2027
EPS, next fiscal year $1.13FY2026 $19.07FY2027 $3.40FY2027
EPS growth, next FY +20.2%FY2026 +6.1%FY2027 +5.6%FY2027
EPS growth, the year after +22.1% +17.4% +11.2%
Revenue, next fiscal year $4.82BFY2026 $328.27BFY2027 $1.53BFY2027
Revenue growth, next FY +2.4%FY2026 -2.7%FY2027 +0.6%FY2027
Revenue growth, the year after +19.4% +19.1% -0.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANCORPAHC
Held by institutions 100.0% 94.7% 51.5%
Institutions holding 526 1,345 210
Change in shares held, QoQ +4.4% +15.7% +3.0%
Institutions buying 246 542 117
Institutions selling 211 612 75
Buyers to sellers 1.17 0.89 1.56

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANCORPAHC
ELAN 1.00 -0.03 0.49
COR -0.03 1.00 0.16
PAHC 0.49 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, COR and PAHC?

Cencora (COR) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Cencora (COR) $69.10B, Phibro Animal Health (PAHC) $1.42B.

Which stock is cheaper, ELAN, COR and PAHC?

Phibro Animal Health (PAHC) trades on the lowest price-to-earnings ratio (Elanco Animal Health (ELAN) -90.2x, Cencora (COR) 22.6x, Phibro Animal Health (PAHC) 13.9x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Elanco Animal Health (ELAN) 23.7x, Cencora (COR) 18.8x, Phibro Animal Health (PAHC) 10.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elanco Animal Health (ELAN) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Cencora (COR) +5.0%, Phibro Animal Health (PAHC) +10.1%.

Which company is more profitable?

Phibro Animal Health (PAHC) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Phibro Animal Health (PAHC) 6.7%). On return on invested capital, Phibro Animal Health (PAHC) leads (Elanco Animal Health (ELAN) 6.9%, Phibro Animal Health (PAHC) 13.9%).

Which stock has performed better?

Over the past year Elanco Animal Health (ELAN) returned the most: Elanco Animal Health (ELAN) +21.8%, Cencora (COR) -1.8%, Phibro Animal Health (PAHC) -19.5%. Over five years, Cencora (COR) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Cencora (COR) +23.4%/yr, Phibro Animal Health (PAHC) +9.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Elanco Animal Health (ELAN) 0.00%, Cencora (COR) 0.00%, Phibro Animal Health (PAHC) 0.01%. Elanco Animal Health (ELAN) and Cencora (COR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Cencora (COR) 33.4%, Phibro Animal Health (PAHC) 56.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, COR and PAHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Phibro Animal Health (PAHC) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.